Avadel Pharma (AVDL) Tops Q2 EPS by 7c, Beats on Revenue

Avadel Pharma (NASDAQ: AVDL) reported Q2 EPS of $0.10, $0.07 better than the analyst estimate of $0.03. Revenue for the quarter came in at $68.13 million versus the consensus estimate of $61.4 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.

You May Also Be Interested In

• John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
• JD Vance says White House wants Fed to cut interest rates
• Volkswagen plans to cut 50,000 jobs by 2030